Nausea is the most common side effect of GLP-1 medicines. Whether you’re taking Ozempic, Wegovy, Saxenda or Mounjaro, stomach upset during the first few weeks of treatment is something many people experience. In this article, you can read why this happens, how long it might last, and what changes to your diet and habits might help.
Why do GLP-1 drugs cause nausea?
GLP-1 agonists work by activating GLP-1 receptors in the gastrointestinal tract and the brain. One of the effects is that gastric emptying slows down: food stays in the stomach longer, which makes you feel full sooner and eat less. This delay is beneficial for weight loss, but at the same time it is the direct cause of nausea, bloating and sometimes vomiting. The body interprets the delayed gastric emptying as a sign that something is wrong, particularly at the start when it is not yet accustomed to the drug’s effects.
The STEP 1 study showed that nausea occurred in just over 44% of participants when using semaglutide 2.4 mg. The good news: clinical studies show that only 4.5% discontinued treatment due to gastrointestinal symptoms. For most people, the symptoms are mild to moderate and clearly subside the longer the treatment continues.
When is the nausea at its worst?
Nausea usually occurs during the first few days to weeks following a dose increase. With semaglutide and tirzepatide, which are injected once a week, the day after the injection can be slightly more difficult. With liraglutide (Saxenda), which is taken daily, the pattern is continuous but you also get used to it more quickly. As the dose stabilises and the body gets used to the drug’s effects, nausea decreases significantly in most people.
It is not without reason that the dosing schedule for GLP-1 drugs is designed with gradual steps. By increasing the dose gradually, the body has time to adjust. Read more about how it works on the Wegovy page on Goodweigh. If you still experience persistent discomfort, discuss with your healthcare professional whether a longer interval between dose increases is advisable.
What can you eat to reduce nausea?
Your diet has a major impact on how you feel during treatment. Fatty, heavy or strongly spiced food further delays gastric emptying, which increases the risk of nausea. Small, light meals spread throughout the day work better than three large portions. Eat slowly, chew thoroughly and stop when you are full, even if the portions are smaller than you are used to.
A consensus statement from international specialists emphasises that practical dietary and lifestyle changes can significantly reduce nausea during GLP-1 treatment. Specifically, it helps to choose foods that are easy to digest: steamed vegetables, rice, soup, boiled meat. Avoid fizzy drinks, alcohol and fast-acting sugars during the first few weeks of treatment or immediately after a dose increase. More information on what works well when using GLP-1 can be found in the article on what to eat if you are using GLP-1 medicines.
When should you contact your doctor?
Mild nausea is a normal and expected part of treatment. However, there are situations when you should contact a doctor. This applies if you are so nauseous that you can no longer eat or drink, if you are vomiting for several days, if you experience signs of dehydration such as a dry mouth, reduced urination or dizziness, or if you have severe abdominal pain in the upper part of your stomach or back. The latter may be a sign of acute pancreatitis, a rare but serious side effect that can occur with all GLP-1 medicines.
A recent review of nausea as a side effect of GLP-1 medicines confirms that side effects in most users are manageable and subside over the course of treatment, but that medical supervision remains necessary in the event of more serious symptoms. At Goodweigh, you always have access to your treating doctor should side effects occur.
Are there differences in nausea between different medicines?
All GLP-1 medicines have a similar side-effect profile regarding the stomach and intestines, but there are subtle differences. Liraglutide (Saxenda) has a shorter half-life and is injected daily, which means you get used to it more quickly but also experience a new injection-related spike every day. Semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) are injected once a week and have a longer half-life, which means the effect is more consistent but the transition when increasing the dose may feel slightly more pronounced.
In addition to the GLP-1 receptor, tirzepatide also activates the GIP receptor. In the SURMOUNT studies, tirzepatide had a similar gastrointestinal profile to semaglutide at the same level of weight loss, with nausea and diarrhoea being the most common side effects. For an overview of all available medicines, visit Goodweigh’s page on weight-loss medicines.
Nausea as a sign, not a reason to stop
Nausea during treatment with GLP-1 medicines is unpleasant, but it is also a sign that the medicine is working. The body is adapting to a new way of processing nutrients. For most people, it disappears within a few weeks, especially if the dose remains stable. Don’t be put off by the first few weeks: the potential for significant weight loss is proven, and the side effects are temporary for most people.
If you are unsure whether treatment with GLP-1 medication is suitable for you, or if you want to know whether you are eligible, read the overview article on when you are eligible for GLP-1 medication. You can also start the intake process directly with Goodweigh, where a doctor will assess your situation and draw up a personalised treatment plan.
References
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
- Ghusn, W., & Hurtado, M. D. (2024). Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars, 10, 100127. https://doi.org/10.1016/j.obpill.2024.100127
- Sievenpiper, J. L., Ard, J., Blüher, M., et al. (2025). Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars, 14, 100228. https://doi.org/10.1016/j.obpill.2025.100228
Your Final Weight Loss Program
Transform your life with our personalized telehealth weight loss program designed for lasting success.
.avif)
